Introduction {#s1}
============

Elucidating the transcriptional programs that determine cell identity during development and regeneration is one of the major goals of current stem cell research. In the past decade, several groups have demonstrated cell plasticity, meaning that a variety of somatic cells can be converted into either pluripotent cells or into other specialised cells by overexpression of specific transcription factors (TFs) ([@bib26]; [@bib37]). For example, the Yamanaka factors *Pou5f1*, *Sox2*, *Klf4* and *Myc* (OSKM) can reprogram somatic cells into induced pluripotent stem cells (iPSCs) ([@bib56]), while lineage-instructive TFs can prompt the transdifferentiation of mouse and human cells into other specialised cell types such as muscle, neural or hematopoietic cells ([@bib59]; [@bib61]; [@bib20]; [@bib25]). In all cases one gene expression program is erased and a new one established. Typically only a small fraction of cells successfully acquire a new fate after TF-overexpression ([@bib33]). For instance, the efficiency of conversion into iPSCs in response to OSKM of diverse primary adult cells such as fibroblasts, keratinocytes, liver cells, neural precursor cells, pancreatic β cells and granulocyte/macrophage progenitors (GMPs) varies widely, ranging between 0.01% for T-lymphocytes and 25% for GMPs ([@bib24]; [@bib39]; [@bib55]; [@bib4]; [@bib1]) for unclear reasons. Identifying the transcriptional signature that render a somatic cell type more amenable to transdifferentiation or reprogramming would teach us about the general mechanisms that control cell fate.

Mechanistic studies of transdifferentiation and reprogramming have established that these are complex processes, where multiple players synergistically establish new transcriptional networks, disrupt old ones and remove epigenetic barriers ([@bib10]). Among the factors that have been shown to affect the efficiency and kinetics of reprogramming are proteins involved in cell cycle progression, chromatin remodelling, and posttranscriptional regulation ([@bib22]; [@bib41]; [@bib15]; [@bib23]; [@bib14]; [@bib9]; [@bib42]; [@bib58]; [@bib60]). Despite these insights, many details about cell fate conversion processes remain unclear. Do cells convert fates as homogeneous populations or through a diversity of paths? Do all cells convert with the same speed? And what are the determinants of variation in the speed and path of cell fate conversion? More fundamentally, if an individual cell is more susceptible for conversion into one fate, is it also more susceptible to conversion into alternative fates? Major obstacles to tackling these questions are the use of bulk samples for analysis, which obscures transcriptional variability in both the starting cell population and during fate conversion, as well as the typically small proportion of responding cells.

To overcome these bottlenecks we employed high-throughput single cell RNA-sequencing (MARS-Seq ([@bib36])) to analyse two highly efficient cell conversion protocols applied to the same starting cell population: i) the transdifferentiation of pre-B cells into macrophages induced by the TF C/EBPa ([@bib61]) and, ii) the reprogramming of pre-B cells into iPSCs, based on the transient expression of C/EBPα followed by the induction of OSKM ([@bib21]). This revealed that both processes, despite their very high efficiency, show heterogeneity for the speed and path of cell fate conversion: cells do not all convert at the same rate and along the same path to the two terminal fates. We computationally predicted and experimentally validated that this heterogeneity arises in the starting cell population. Cells with low Myc activity transdifferentiate into macrophages efficiently and directly but fail to reprogram. In contrast, cells with high Myc activity reprogram at a very high efficiency but have a lower propensity to transdifferentiate and do so by a more indirect path. Strikingly, Myc levels correlate with the reprogramming efficiency of diverse hematopoietic and non-hematopoietic cell types. These results illustrate how single cell analysis can characterise heterogeneity in cell fate conversion processes and identify its underlying causes.

Results {#s2}
=======

Single cell analysis of highly efficient transdifferentiation and reprogramming from the same cell population {#s2-1}
-------------------------------------------------------------------------------------------------------------

We isolated CD19^+^ pre-B cells from the bone marrow of reprogrammable mice carrying a drug-inducible reverse tetracycline trans-activator (M2rtTA; hereafter abbreviated as rtTA) in the *Rosa26* locus, a polycistronic expression cassette in the collagen type I (*Col1a1*) locus, which contains four mouse derived cell reprogramming genes (*Pou5f1*, *Sox2*, *Klf4* and *Myc*, OSKM) separated by three sequences encoding 2A self-cleaving peptides, and the POU5F1*-GFP* transgene ([@bib21]; [@bib13]). Pre-B cells were then infected with a C/EBPaER-hCD4 retrovirus, sorted for hCD4 expression and induced to either transdifferentiate into macrophages or reprogram into iPSCs. To induce the macrophage fate, we treated the cells with beta-estradiol (E2), which activates C/EBPα. To induce the iPSC fate, we first incubated them with E2 for 18 hr to transiently activate C/EBPa, generating a 'poised state', washed out the compound and then added doxycycline to induce OSKM ([@bib22]; [@bib21]). For transdifferentiation, we collected cells before (0 hr) and after 6 hr, 18 hr, 42 hr, 66 hr and 114 hr of C/EBPα induction; for reprogramming, samples were prepared at days 2, 4, 6 and 8 after OSKM induction of 18 h C/EBPa-pulsed cells ([Figure 1a](#fig1){ref-type="fig"}), to be consistent with our previous bulk studies ([@bib22]; [@bib21]). We collected two pools of 192 cells at each time point and sequenced their RNA using MARS-Seq ([@bib36]). After quality control and filtering, we obtained expression profiles for 17,183 genes in 3,152 cells. After performing dimensionality reduction and correction for global batch effects ([Figure 1---figure supplement 1a--c](#fig1s1){ref-type="fig"}) we used independent component analysis (ICA) to extract specific gene expression signatures ([Supplementary files 1](#supp1){ref-type="supplementary-material"}--[2](#supp2){ref-type="supplementary-material"} and [Figure 1---figure supplement 1d](#fig1s1){ref-type="fig"}). We then compared independent components from our data with components extracted from a comprehensive atlas of 272 murine cell types ([@bib35]) ([Figure 1---figure supplement 2a--c](#fig1s2){ref-type="fig"}). The components were further characterised by Fisher's test-based gene set enrichment analysis (GSE, [Supplementary files 3](#supp3){ref-type="supplementary-material"}--[4](#supp4){ref-type="supplementary-material"}). Finally, we reconstructed batch corrected gene expression data using selected components ([Figure 1---figure supplement 2d--e](#fig1s2){ref-type="fig"}).

![Single cell gene expression analysis of B cell to macrophage transdifferentiation and B cell to iPSC reprogramming.\
(**a**) Overview of the experimental design, showing time points analysed. (**b**) Single cell projections onto the first two diffusion components (DC1 and DC2). c-f, as in b, with top 50% of cells expressing selected markers for B cells in red (**c**) GMP/granulocytes in orange (**d**) monocytes in purple (**e**) macrophages in light blue (**f**) and pluripotent cells in orange-red (g). (**h-i**) Projection of transdifferentiating cells onto B cell-, macrophage-, and monocyte-specific independent components (**h**) and reprogramming cells onto, B cell-, mid- and late- pluripotency specific independent components as defined in [Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"} (**i**).](elife-41627-fig1){#fig1}

Cell conversion trajectories suggest that transcription factor induced transdifferentiation and reprogramming are deterministic {#s2-2}
-------------------------------------------------------------------------------------------------------------------------------

Visualising the data using diffusion maps ([@bib29]) revealed branching between transdifferentiation and reprogramming at the 18 hr time-point, with cohorts of cells moving along two distinct trajectories and reaching homogeneous final cell populations consisting of either induced macrophage (iMac) or iPSC-like cells, respectively ([Figure 1b](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2f](#fig1s2){ref-type="fig"}, [Figure 1---figure supplement 3a](#fig1s3){ref-type="fig"}). We observed no branching into alternative routes, in contrast to what has been described for the transdifferentiation of fibroblasts into neurons ([@bib57]), muscle cells ([@bib12]) or iPSCs ([@bib28]; [@bib52]). Our findings therefore support the notion that both transcription factor-induced transdifferentiation and reprogramming represent deterministic processes. However, we observed that D2-D4 cells transit through a state that partially resembles neuronal cell types ([Figure 1---figure supplement 3a](#fig1s3){ref-type="fig"}) although the significance of this is unclear as D2 and D4 cells are overall quite dissimilar to any cell type within the mouse cell reference atlas ([@bib35]) ([Figure 1---figure supplement 3b](#fig1s3){ref-type="fig"}). Of note, D6 cells are more similar to inner cell mass cells (ICM) at the blastocyst stage than D8 cells, which are in turn more similar to ESCs ([Figure 1---figure supplement 3a](#fig1s3){ref-type="fig"}). This observation is reminiscent of recent findings showing that cells at intermediate stages of mouse embryo fibroblast (MEF) to iPSC reprogramming exhibit an increased ability to generate diverse somatic tissues upon injection into tetraploid blastocysts ([@bib2]).

C/EBPa expression silences the B cell program and induces a progenitor state followed by a monocyte/macrophage program {#s2-3}
----------------------------------------------------------------------------------------------------------------------

Already 6 h hours after C/EBPa expression cells strongly downregulated B cell-specific transcripts, such as *Cd19* that encodes a B lineage transmembrane protein*; Cd79a, Cd79b, Vpreb1, Vpreb2, Vpreb3* and *Blnk* that are involved in signalling of the B cell receptor complex; and *Blk* that encodes a B lymphocyte specific kinase. Subsequently, after 18 hr they started to transiently express the granulocyte/GMP restricted genes myeloperoxidase (*Mpo*) and the serine neutrophil protease 3 (*Prtn3*). Finally, after sustained C/EBPa expression additional myeloid markers become expressed, including the macrophage specific colony stimulating receptor gene (*Csf1r*), lysozyme (*Lyz1 and 2*), granulocyte collagenase 8 (*Mmp8*), macrophage scavenger receptor (*Msr1*), myeloid restricted serine protease C (C*tsc*) and the myeloid cytokine dependent chemokine 6 (C*cl6*) ([Figure 1c--f](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3c--j](#fig1s3){ref-type="fig"}, [Supplementary files 6](#supp6){ref-type="supplementary-material"} and [7](#supp7){ref-type="supplementary-material"}).

OSKM expression in C/EBPa-pulsed cells further accelerates B cell silencing and leads to the sequential upregulation of the pluripotency program {#s2-4}
------------------------------------------------------------------------------------------------------------------------------------------------

After OSKM induction of 18 h C/EBPa-pulsed cells, endogenous *Pou5f1* (*Oct4*) is activated at day 2, followed by expression of *Nanog* and *Sox2* at days 6 and 8, respectively ([Figure 1g](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3g--i](#fig1s3){ref-type="fig"}). This is consistent with the sequential expression of the three key pluripotency factor genes revealed by RNA sequencing of bulk populations during reprogramming in our system ([@bib22]; [@bib54]). OSKM induction further downregulates B cell genes and inflammatory genes and upregulates biosynthetic pathway and energy metabolism genes at D2 ([Figure 1---figure supplement 3k](#fig1s3){ref-type="fig"}, [Supplementary files 6](#supp6){ref-type="supplementary-material"}--[7](#supp7){ref-type="supplementary-material"}). This is followed by activation of proliferation and cell cycle genes at D6 and histone deacetylase and methylase genes at D8 ([Figure 1---figure supplement 3l](#fig1s3){ref-type="fig"}, [Supplementary files 6](#supp6){ref-type="supplementary-material"}--[7](#supp7){ref-type="supplementary-material"}. In short, OSKM expression in C/EBPa pulsed cells further induces B cell silencing and activates pluripotency genes in a sequential manner.

Heterogeneity at intermediate time points suggests asynchrony in transdifferentiation timing {#s2-5}
--------------------------------------------------------------------------------------------

Visualising single cells in diffusion maps ([Figure 1b](#fig1){ref-type="fig"}) or in the expression space spanned by B cell, monocyte and macrophage programs ([Figure 1h](#fig1){ref-type="fig"}) shows that at intermediate time points some cells are highly similar to cells at earlier time points while others are similar to cells at later time points. For example, at 42 hr after C/EBPa induction there are three clusters of cells that are spread along the transdifferentiation trajectory ([Figure 1h](#fig1){ref-type="fig"}, magenta). Consistently, the expression of key marker genes at 42 hr of transdifferentiation is highly variable, with some cells expressing levels comparable to cells at earlier time points and others expressing levels comparable to cells at later time points ([Figure 1---figure supplement 4a](#fig1s4){ref-type="fig"}). These observations suggest heterogeneity in the speed of transdifferentiation conversion (i.e. asynchrony) among single cells despite the fact that transdifferentiation results in a quite homogeneous final cell population.

Rapid transdifferentiation into macrophages is associated with low Myc component {#s2-6}
--------------------------------------------------------------------------------

To identify potential causes of this apparent asynchronous behaviour, we define each cell progression towards a macrophage state as the genome-wide similarity of its transcriptome to the bone-marrow-derived-macrophage (BMDM) transcriptome from the reference atlas ([@bib35]) (see Methods). We can observe also using this metric that at 42 hr some cells already resemble macrophages while others are still quite dissimilar, which is consistent with asynchrony in transdifferentiation ([Figure 2a](#fig2){ref-type="fig"}). We then determined which gene expression signature extracted from our single cell expression data correlates best with the progression towards the macrophage state ([Figure 2a](#fig2){ref-type="fig"}) at each time-point (excluding the cell type-specific signatures directly involved in transdifferentiation, that are the B cell, monocyte, granulocyte, and macrophage programs). The most correlated component is highly enriched in Myc target genes (component five in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, henceforth called 'Myc component', see Fisher's test-based enrichment analysis of Molecular Signature database hallmark gene set collection ([@bib44]) in [Supplementary file 4](#supp4){ref-type="supplementary-material"}) and negatively correlates with the progression of cells at intermediate time points of transdifferentiation ([Figure 2b](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The Myc component varies extensively across cells within each time point but overall changes little during transdifferentiation ([Figure 2c](#fig2){ref-type="fig"}). These data therefore suggest that cells with lower Myc component transdifferentiate more rapidly into macrophages.

![Myc activity correlates with differences in single cell transdifferentiation and reprogramming trajectories.\
(**a**) Distribution of gene expression similarity between single cells and reference bone marrow derived macrophages ([@bib35]) (acquisition of macrophage state) during transdifferentiation. (**b**) Correlation between the Myc component and acquisition of macrophage state from a; start and end time points were omitted to improve clarity (they are presented in [Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). (**c**) Myc component at the various transdifferentiation time points. d-f, Single cell trajectories of the B cell state (**d**), the GMP state (**e**) and the granulocyte state (**f**) related to the acquisition of the macrophage state during transdifferentiation. The cells at the respective time points are coloured according to Myc component levels. (**g**) Distribution of expression similarity between single cells and reference embryonic stem cells (ESCs) during reprogramming. (**h**) Correlation between Myc component and acquisition of pluripotency from g. (**i**) Myc component at the various reprogramming time points. (**j-l**) Single cell trajectories of the B cell state (**j**), GMP state (**k**) and inner cell mass state (**l**) related to the acquisition of the pluripotent state (ESCs) (see also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).](elife-41627-fig2){#fig2}

Cells with high Myc component transdifferentiate via a pronounced GMP-like cell state {#s2-7}
-------------------------------------------------------------------------------------

We next tested how the Myc component relates to the loss of the B cell state during transdifferentiation. For each cell\'s transcriptome, we therefore computed its similarity to the pre-B cell state and compared this with its similarity to the macrophage state. This shows that low Myc component is more strongly associated with a rapid gain of the macrophage state than with a rapid loss of the B cell state (the cells go from high Myc to low Myc component mainly from left to right along the macrophage axis rather than from top to bottom along the pre-B cell axis; [Figure 2d](#fig2){ref-type="fig"}). Similarly, we explored the acquisition of a transient GMP-like state during transdifferentiation. This shows that high Myc component cells (green/blue) resemble GMPs up to 42 hr after C/EBPa induction whereas low Myc component cells (yellow/orange) only show moderate similarity to GMPs at 18 hr after induction, suggesting that higher Myc component is associated with a larger and more persistent induction of a GMP-like state ([Figure 2e](#fig2){ref-type="fig"}). However, this is not the case for the induction of a transient granulocyte-like state ([Figure 2f](#fig2){ref-type="fig"}). Taken together, these analyses suggest that high Myc component cells acquire the macrophage fate more slowly than low Myc component cells, passing through a more pronounced induction of a GMP-like state.

Efficient reprogramming correlates with high Myc component {#s2-8}
----------------------------------------------------------

Next, as we did for the transdifferentiation, we define each cell progression towards pluripotency as the genome-wide similarity of its transcriptome to the ESC transcriptome from the reference atlas ([@bib35]) (see Methods). At intermediate time points (D2 and D4) the similarity to ESC is quite variable, with cells that already resemble ESCs and others that are still quite dissimilar ([Figure 2g](#fig2){ref-type="fig"}), suggesting an asynchronous behaviour during reprogramming as well. We then searched for expression signatures that best correlate with the progression of individual cells toward pluripotency within each time-point during reprogramming. The Myc component again correlates best with progression of cell fate conversion, especially at early stages. However, in contrast to what was observed during transdifferentiation, high Myc component positively correlates with a more advanced state of reprogramming ([Figure 2h](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Moreover - and also different to what was observed during transdifferentiation - the Myc component increases during reprogramming ([Figure 2i](#fig2){ref-type="fig"}).

We next explored how the Myc component relates to the loss of B cell program during reprogramming ([Figure 2j](#fig2){ref-type="fig"}). As for transdifferentiation cells go from low Myc to high Myc component from left to right along the similarity to ESC (x axis) rather than from top to bottom along the similarity to pre-B cells (y axis), suggesting that high Myc component correlates more with the gain of pluripotency rather than with the loss of the B cell program. As mentioned before, D6 cells are more similar to early embryonic stages than D8 cells. However, exploring how Myc component relates to the similarity to inner cell mass (ICM) cells during reprogramming shows that cells with high Myc component maintain a high similarity to ICM cells at D8. In contrast, cells with low Myc component show low similarity to ICM cells at D8 ([Figure 2k](#fig2){ref-type="fig"}, [Figure 2---figure supplement 3g](#fig2s3){ref-type="fig"}). Interestingly, low Myc component cells also acquire a placental-like signature at D8 ([Figure 2l](#fig2){ref-type="fig"}, [Figure 2---figure supplement 3h](#fig2s3){ref-type="fig"}), suggesting that low Myc component cells may eventually branch out towards this extra-embryonic lineage.

Together, our findings reveal a correlation between high Myc component and cell susceptibility to reprogramming towards pluripotency. They also suggest that a subset of low Myc component cells along this trajectory acquires properties of extraembryonic cells.

Variation in Myc component reflects pre-existing variation in the starting cell population {#s2-9}
------------------------------------------------------------------------------------------

What is the origin of the Myc component heterogeneity? Is it due to a differential response of lineage instructive transcription factors of an essentially homogenous population or to a heterogeneity in the starting population? Examining the uninduced pre-B cells shows a variable Myc component which also partially correlates with higher expression of both G1/S and G2/M phase cell cycle genes ([Figure 3a](#fig3){ref-type="fig"}). Visualising transcriptomes of uninduced pre-B cells using t-SNE indeed revealed sub-structure associated with the Myc component ([Figure 3---figure supplement 1a](#fig3s1){ref-type="fig"}). In addition, the Myc component in our single pre-B cells scales with the total mRNA content of each cell which varies over a three-fold range ([Figure 3b](#fig3){ref-type="fig"}). This suggests a Myc-associated heterogeneity in cell size in the starting cell population. During B cell development in the bone marrow, large pre-BII cells undergo a proliferation burst and following activation of the pre-B cell receptor differentiate into quiescent small pre-BII cells via Bcl6-induced transcriptional repression of *Myc* ([@bib34]). These events constitute an important immunological checkpoint, required for the initiation of light chain immunoglobulin rearrangements ([@bib48]). Thus, we hypothesised that the heterogeneity in the starting pre-B cell population could reflect variability along this B cell developmental transition. To test this hypothesis, we compared our single cell data with bulk expression data of cells at various stages of B cell development ([@bib34]; [@bib49]). This revealed that cells with higher Myc component are indeed more similar to large and cycling pre-BII cells, while cells with lower Myc component are more similar to small and non-cycling pre-BII cells ([Figure 3c](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1b](#fig3s1){ref-type="fig"}).

![Two types of pre-B cells exhibit distinct cell conversion plasticities.\
(**a**) Heatmap showing the expression of Myc target genes, G1/S and G2/M specific genes in the starting pre-B cells sorted by Myc component. (**b**) Pearson's correlation between total mRNA molecules per cell and Myc component. (**c**) Similarity score of single cells binned by Myc component (bottom 20%, mid and top 20%) with reference large and small pre-BII cells. (**d**) Representative FACS plot of starting pre-B cells showing forward (FSC) and side scatter (SSC). (**e**) Representative FACS analysis of Myc levels detected in the 30% largest and the 30% smallest pre-B cell fractions. (**f**) FACS plots of myeloid marker (Mac-1) and B cell marker (CD19) expression during induced transdifferentiation of sorted large and small pre-BII cells. (**g**) Quantification of the results shown in f (n = 3 biological replicates, error bars indicate mean ± s.d. Statistical significance was determined using multiple t-test with 1% false discovery rate). (**h**) Visualisation of iPSC-like colonies (stained by alkaline phosphatase) 12 days after OSKM induction of sorted large and small pre-BII cells. (**i**) Quantification of the results shown in h (n = 10 biologically independent samples (cell cultures) for large and n = 9 biologically independent samples (cell cultures) for small cells, with error bars indicating mean ±s.d. Statistical significance was determined using a two-tailed unpaired Student's t-test). (**j**) Scatterplot showing the correlation between Myc expression ([@bib36]) in different starting hematopoietic cell types (x-axis) and their corresponding (logit transformed) reprogramming efficiency (y-axis). GMP: granulocyte monocyte progenitor, CMP: common myeloid progenitor, CLP: common lymphoid progenitor, LT-HSC: long term hematopoietic stem cells, HSC-P: short term hematopoietic stem cells. (**k**) Correlation between Myc component and reprogramming efficiency in various somatic cell types, including the hematopoietic cells shown in j.](elife-41627-fig3){#fig3}

Taken together, our analyses suggest a pre-existing heterogeneity in the starting cell population, corresponding to large and small pre-BII cells. Moreover, they suggest that small pre-BII cells should transdifferentiate faster but reprogram more slowly, while large pre-BII cells should transdifferentiate more slowly but reprogram faster.

Large and small pre-B cells differ reciprocally in their respective transdifferentiation and reprogramming propensities {#s2-10}
-----------------------------------------------------------------------------------------------------------------------

To test these hypotheses, we analysed our starting pre-B cell population by flow cytometry and found that it can be resolved into two discrete subpopulations, with 72% large and 25% small cells ([Figure 3d](#fig3){ref-type="fig"}). Intracellular staining of Myc monitored by flow cytometry confirmed that the large cells express abundant levels of the transcription factor while the smaller cells are essentially Myc negative ([Figure 3e](#fig3){ref-type="fig"}, [Figure 3---figure supplements 1c](#fig3s1){ref-type="fig"} and [2a](#fig3s2){ref-type="fig"}). The two subpopulations also showed the known difference in cycling between large and small pre-BII cells ([@bib48]), with the large cells incorporating 400 times more EdU within 2 hr than the small cells ([Figure 3---figure supplements 1d](#fig3s1){ref-type="fig"} and [2b](#fig3s2){ref-type="fig"}).

To determine whether the two types of B cell progenitors differ in their plasticity, we isolated them from reprogrammable mice and tested their conversion ability into either macrophages or iPSCs. In response to a continuous exposure to C/EBPa the small pre-BII cells upregulated the macrophage marker Mac-1 faster and downregulated CD19 slightly more rapidly than large pre-BII cells ([Figure 3f--g](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2c](#fig3s2){ref-type="fig"}). Similarly, the small cells acquired higher granularity and a slightly increased volume compared to the large cells, both markers of mature myeloid cells ([Figure 3---figure supplement 1e](#fig3s1){ref-type="fig"}). In stark contrast, when 18 hr pulsed cells (also designated Ba' cells ([@bib22]; [@bib21])) were tested for reprogramming ability in response to OSKM induction, large pre-BII cells generated 30x times more iPSC colonies than small pre-B cells ([Figure 3h--i](#fig3){ref-type="fig"}), which, as opposed to large pre-B cells, die out during the reprogramming time course ([Figure 3---figure supplement 1f](#fig3s1){ref-type="fig"}).

Previous work testing different times of C/EBPa induction in pre-B cells before OSKM induction showed that an 18 hr treatment elicited a maximal enhancement of the cells' reprogramming efficiency ([@bib21]). Longer exposures, driving the cells into a macrophage-like state, decreased the efficiency ([@bib21]), raising the possibility that an accelerated transdifferentiation of the small cells towards macrophages moves them out of the time window required for high responsiveness. If this was the case, a shorter pulse of C/EBPa should increase the reprogramming responsiveness of the small cells. However, when testing the effect of a 6 h C/EBPa pulse we found that the small cells remained highly resistant to reprogramming, exhibiting fewer iPSC colonies than with the 18 hr pulse ([Figure 3---figure supplement 1g](#fig3s1){ref-type="fig"}). Taken together, our results indicate that large and small pre-BII cells exhibit intrinsic differences in their cell conversion plasticities.

Reprogramming susceptibility correlates with high Myc levels in a broad variety of somatic cell types {#s2-11}
-----------------------------------------------------------------------------------------------------

The observed correlation between high Myc levels and the propensity of pre-B cells for reprogramming into iPSCs could reflect a peculiarity of lymphoid progenitors. We therefore asked whether Myc activity also correlates with the reprogramming efficiency of other somatic cells, examining existing datasets of 9 hematopoietic and 11 non-hematopoietic cell types ([@bib56]; [@bib24]; [@bib39]; [@bib55]; [@bib1]). Strikingly, we found that high Myc expression levels in the starting cell type strongly correlate with a high iPSC reprogramming efficiency across all nine different hematopoietic cell types (R = 0.93, p\<0.0001, [Figure 3j](#fig3){ref-type="fig"}), with GMPs and multipotent progenitors (MPPs) exhibiting the highest levels of Myc component and highest reprogramming efficiencies ([Figure 3k](#fig3){ref-type="fig"}). Furthermore, Myc component levels also correlate with the reprogramming efficiency of various non-hematopoietic cell types (R = 0.66, p=0.0016). These findings show that high Myc expression levels are strongly predictive for the reprogramming susceptibility of a broad variety of somatic cell types.

Discussion {#s3}
==========

Here we have described the transdifferentiation and cell reprogramming trajectories of pre-B cells into either macrophages or iPS cells at the single cell level. The observed high frequencies of both cell type conversions are consistent with deterministic processes. However, our experiments also revealed unexpected heterogeneity among cells in the speed and paths by which transcription factors induce transdifferentiation and reprogramming. Our computational analyses made non-trivial predictions about the origins and the consequence of this heterogeneity, predicting an inverse relationship between the ability of cells to either transdifferentiate or to reprogram. These predictions could be experimentally validated, showing the presence of two distinct cell subsets in the starting pre-B cell population, corresponding to previously described large pre-BII cells and small pre-BII cells, into which they normally differentiate. Surprisingly, we found that these two cell types differ in their cell conversion plasticities: while large pre-BII cells efficiently reprogram into iPSCs through a GMP-like cell state but transdifferentiate more slowly into macrophages, small pre-BII cells reprogram much less efficiently into iPSCs but transdifferentiate more rapidly ([Figure 4](#fig4){ref-type="fig"}).

![Summary of the main findings.](elife-41627-fig4){#fig4}

The finding that cell propensity for transdifferentiation and reprogramming are inversely coupled suggests that the two types of plasticity are intrinsically different. Moreover, the Myc component correlates with both types of plasticity and in a reciprocal manner. Strikingly, high Myc levels correlate with high reprogramming efficiencies not only in hematopoietic progenitors but also in a wide range of other somatic cell types. Consistent with our findings, it has been reported that expression of endogenous *Myc* is essential for efficient reprogramming of MEFs into pluripotent cells ([@bib32]; [@bib63]). Together, our observations suggest an important role of Myc for the plasticity of both hematopoietic and non-hematopoietic cells. We also discovered that a subset of low Myc component cells at D8 of reprogramming resembles extra-embryonic cell types, reminiscent of an earlier report ([@bib50]).

The Myc effect could be mediated at least in part by one of the different activities reported for the factor, or a combination thereof. These include its ability to induce cell proliferation ([@bib19]), its association with global chromatin changes ([@bib40]; [@bib38]), its capacity to transcriptionally activate and amplify genes, including those essential for proliferation ([@bib45]) and its induction of metabolic changes ([@bib19]). The unique features of Myc are also likely central for its capacity to act as a major driver of cancer ([@bib19]) and for its role in early embryonic development ([@bib53]). However, high Myc expression in somatic cells is not sufficient to enable their efficient OSKM-induced reprogramming, as we found that large pre-BII cells must still be primed by the transient expression of C/EBPa ([@bib21]). This might be related to C/EBPa's multiple functions including its ability to act as a pioneer transcription factor ([@bib58]; [@bib62]), to activate key pluripotency TFs such as Klf4, to recruit chromatin related factors including LSD1/Kdm1a, Hdac1, Brd4 and Tet2 ([@bib22]; [@bib51]) and/or to induce changes in genome topology preceding pluripotent transcription factor expression ([@bib54]). A similar scenario may also play out during OSKM-induced MEF to iPSC reprogramming: here pluripotency factors first target and inactivate enhancers of specific somatic TFs, including *Cebpa, Cebpb*, *Fra1* and *Runx1*, before engaging pluripotency gene enhancers ([@bib16]). It therefore appears that efficient reprogramming of somatic into pluripotent stem cells requires three waves of transcription factor activity: i) Expression of high Myc levels in the starting cells, ii) transient expression of specific lineage regulators and iii) activation of key pluripotency transcription factors. It is tempting to speculate that similar transcriptional waves are also required for some of the earliest developmental decisions such as for the formation of pluripotent and extraembryonic cells during pre-implantation embryo development.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\           Designation                   Source or reference           Identifiers                                                              Additional\
  (species) or resource                                                                                                                                        information
  ----------------------- ----------------------------- ----------------------------- ------------------------------------------------------------------------ --------------------
  Gene\                   cebpa                         NA                            Ensembl:\                                                                
  (*Mus musculus*)                                                                    ENSG00000245848                                                          

  Strain, strain\         Pou5f1GFP transgenic\         [@bib8]                       NA                                                                       Strain: C57Bl\
  background\             mouse                                                                                                                                /6 × DBA/2
  (*Mus musculus*)                                                                                                                                             

  Strain, strain\         Gt(ROSA)26Sortm1\             The Jackson Laboratory        Cat\# 011004;\                                                           Strain:\
  background\             (rtTA\*M2)Jae Col1a1tm3\                                    RRID:[IMSR_JAX:011004](https://scicrunch.org/resolver/IMSR_JAX:011004)   (C57BL/6 × 129S4/\
  (*Mus musculus*)        (tetO-Pou5f1,-Sox2,-\                                                                                                                SvJae)F1
                          Klf4,-Myc)Jae/J                                                                                                                      

  Strain, strain\         Pou5f1-GFP\                   [@bib36],\                    NA                                                                       Strain: C57BL\
  background\             OSKM-reprogrammable           [@bib22]                                                                                               /6 × 129
  (*Mus musculus*)                                                                                                                                             

  Cell line\              PlatE retroviral\             Cell Biolabs                  Cat\# RV-101;\                                                           
  (*Homo sapiens*)        packaging cell line                                         RRID: [CVCL_B488](https://scicrunch.org/resolver/CVCL_B488)              

  Cell line\              S17 stromal cell line         From Dr. Dorshkind,\          RRID: [CVCL_E226](https://scicrunch.org/resolver/CVCL_E226)              
  (*Mus musculus*)                                      UCLA.\                                                                                                 
                                                        ([@bib17])                                                                                             

  Cell line\              Mouse Embryonic\              GIBCO                         Cat\# A34180                                                             
  (*Mus musculus*)        Fibroblasts, Irradiated                                                                                                              

  Recombinant\            pMSCV-Cebpa-IRES-hCD4         Produced in-house,\           NA                                                                       
  DNA reagent                                           ([@bib11])                                                                                             

  Antibody                Mouse monoclonal\             BD Biosciences                Cat\# 555349;\                                                           Dilution\
                          APC Anti-human\                                             RRID: [AB_398593](https://scicrunch.org/resolver/AB_398593)              used = 1:400
                          CD4 (RPA-T4)                                                                                                                         

  Antibody                Mouse monoclonal\             eBioscience                   Cat\# 13--0049;\                                                         Dilution\
                          biotin anti-human\                                          RRID:[AB_466337](https://scicrunch.org/resolver/AB_466337)               used = 1:400
                          CD4 (RPA-T4)                                                                                                                         

  Antibody                Rat monoclonal\               BD Biosciences                Cat\# 553142;\                                                           Dilution\
                          Anti-Mouse CD16/CD32\                                       RRID: [AB_394654](https://scicrunch.org/resolver/AB_394654)              used = 1:400
                          (Mouse BD Fc Block)                                                                                                                  

  Antibody                Rat monoclonal\               BD Biosciences                Cat\# 552854;\                                                           Dilution\
                          Pe-cy7 Anti-mouse\                                          RRID:[AB_394495](https://scicrunch.org/resolver/AB_394495)               used = 1:400
                          CD19 (1D3)                                                                                                                           

  Antibody                Mouse monoclonal\             BD Biosciences                Cat\# 561015;\                                                           Dilution\
                          APC Anti-mouse\                                             RRID:[AB_10561676](https://scicrunch.org/resolver/AB_10561676)           used = 1:400
                          CD11b (44)                                                                                                                           

  Antibody                Rat monoclonal\               BD Biosciences                Cat\# 553784;\                                                           Dilution\
                          biotin Anti-mouse\                                          RRID: [AB_395048](https://scicrunch.org/resolver/AB_395048)              used = 1:400
                          CD19 (1D3)                                                                                                                           

  Antibody                Rabbit monoclonal\            Abcam                         Cat\# ab32072;\                                                          Dilution\
                          \[Y69\] to c-Myc                                            RRID:[AB_731658](https://scicrunch.org/resolver/AB_731658)               used = 1:76

  Antibody                Goat Polyclonal\              Life technologies             Cat\# A32733;\                                                           Dilution\
                          Anti-Rabbit IgG\                                            RRID:[AB_2633282](https://scicrunch.org/resolver/AB_2633282)             used = 1:2000
                          H and L Alexa Fluor 647                                                                                                              

  Strain, strain\         E. coli: BL21(DE3)\           New England Biolabs           Cat\# C2527I                                                             
  background\             Competent                                                                                                                            
  (*Escherichia coli*)                                                                                                                                         

  Peptide,\               Recombinant\                  Peprotech                     Cat\# 217--17                                                            
  recombinant protein     murine IL-7                                                                                                                          

  Peptide,\               Recombinant\                  Peprotech                     Cat\# 214--14                                                            
  recombinant\            murine IL-4                                                                                                                          
  protein                                                                                                                                                      

  Peptide,\               Recombinant\                  Peprotech                     Cat\# 210--15                                                            
  recombinant\            murine IL-15                                                                                                                         
  protein                                                                                                                                                      

  Peptide,\               ESGRO Recombinant\            Merk Millipore                Cat\# ESG1106                                                            
  recombinant\            mouse LIF protein                                                                                                                    
  protein                                                                                                                                                      

  Commercial\             Click-IT EdU\                 Invitrogen                    Cat\# C10425                                                             
  assay or kit            Cytometry assay kit                                                                                                                  

  Commercial\             miRNeasy mini kit             Qiagen                        Cat\# 217004                                                             
  assay or kit                                                                                                                                                 

  Commercial\             SYBR Green QPCR\              Applied Biosystems            Cat\# 4309155                                                            
  assay or kit            Master Mix                                                                                                                           

  Commercial\             Alkaline Phosphatase\         Stemgent                      Cat\# 00--0055                                                           
  assay or kit            Staining Kit II                                                                                                                      

  Commercial\             High Capacity\                Applied Biosystems            Cat\# 4387406                                                            
  assay or kit            RNA-to-cDNA kit                                                                                                                      

  Chemical\               17β-estradiol                 Merck Millipore               Cat\# 3301                                                               
  compound, drug                                                                                                                                               

  Chemical\               MEK inhibitor\                Selleckchem                   Cat\# S1036                                                              
  compound, drug          (PD0325901)                                                                                                                          

  Chemical\               Doxycycline hyclate           Sigma-Aldrich                 Cat\# D9891                                                              
  compound, drug                                                                                                                                               

  Chemical\               L-Ascorbic Acid               Sigma-Aldrich                 Cat\# A92902                                                             
  compound, drug                                                                                                                                               

  Chemical\               GSK3b inhibitor\              Selleckchem                   Cat\# S1263                                                              
  compound, drug          (CHIR-99021)                                                                                                                         

  Other                   DMEM Medium                   Gibco                         Cat\# 12491015                                                           

  Other                   RPMI 1640 Medium              Gibco                         Cat\# 12633012                                                           

  Other                   Knockout-DMEM                 Gibco                         Cat\# 10829018                                                           

  Other                   Neurobasal Medium             Gibco                         Cat\# 21103049                                                           

  Other                   DMEM-F12 Medium               Gibco                         Cat\# 12634010                                                           

  Other                   Fetal Bovine Serum,\          Gibco                         Cat\# 10270--106                                                         
                          E.U.-approved, South\                                                                                                                
                          America origin                                                                                                                       

  Other                   Embryonic stem-cell\          Gibco                         Cat\# 10270--106                                                         
                          FBS, qualified, US origin                                                                                                            

  Other                   KnockOut\                     Gibco                         Cat\# A3181502                                                           
                          Serum Replacement                                                                                                                    

  Other                   Pen Strep                     Gibco                         Cat\# 15140122                                                           

  Other                   L-Glutamine (200 mM)          Gibco                         Cat\# 25030081                                                           

  Other                   Sodium Pyruvate (100 mM)      Gibco                         Cat\# 11360070                                                           

  Other                   MEM Non-Essential\            Gibco                         Cat\# 11140068                                                           
                          Amino Acids Solution (100X)                                                                                                          

  Other                   2-Mercaptoethanol             Invitrogen                    Cat\# 31350010                                                           

  Other                   N-2 Supplement (100X)         Gibco                         Cat\# 17502048                                                           

  Other                   B-27 Serum-Free\              Gibco                         Cat\# 17504044                                                           
                          Supplement (50X)                                                                                                                     

  Other                   TrypLE Express\               Gibco                         Cat\# 12605010                                                           
                          Enzyme (1X)                                                                                                                          

  Other                   Trypsin-EDTA (0.05%)          Gibco                         Cat\# 25300054                                                           

  Other                   MACS Streptavidin\            Miltenyi Biotec               Cat\# 130-048-101                                                        
                          MicroBeads                                                                                                                           

  Other                   MACS LS\                      Miltenyi Biotec               Cat\# 130-042-401                                                        
                          magnetic columns                                                                                                                     

  Software, algorithm     R                             R Project for Statistical\    RRID:[SCR_001905](https://scicrunch.org/resolver/SCR_001905)             
                                                        Computing\                                                                                             
                                                        <http://www.r-project.org/>                                                                            
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice and cell cultures {#s4-1}
----------------------

We used 'reprogrammable mice' containing a doxycycline-inducible OSKM cassette and the tetracycline transactivator ([@bib13]). CD19^+^ pre-B cells were isolated from the bone marrow of these mice using monoclonal antibody to CD19 (clone 1D3, BD Pharmingen \#553784) and MACS sorting (Miltenyi Biotech). Cell purity was confirmed to be \>98% CD19+by FACS using an LSRII machine (BD). After isolation, B cells were grown in RPMI medium supplemented with 10% FBS and 10 ng/ml IL-7 (Peprotech), L-glutamine, nonessential amino acids, β-mercaptoethanol (Life Technologies) as well as penicillin/streptomycin. Mouse embryo fibroblasts (MEFs) were isolated from E13.5 mouse and expanded in DMEM supplemented with 10% FBS, L-glutamine and penicillin/streptomycin. Cultures were routinely tested for mycoplasma contamination. Animal experiments were approved by the Ethics Committee of the Barcelona Biomedical Research Park (PRBB) and performed according to Spanish and European legislation.

Transdifferentiation and reprogramming experiments {#s4-2}
--------------------------------------------------

For transdifferentiation pre-B cells were infected with C/EBPαER-hCD4 retrovirus produced by the PlatE retroviral packaging cell line (Cell Biolabs, \# RV-101). The cells were expanded for 48 hr on Mitomycin C-inactivated S17 feeders grown in RPMI medium supplemented with 10 ng/mL each of IL-7 (Peprotech) and hCD4^+^ were sorted (FACSaria, BD). For transdifferentiation C/EBPa was induced by treating the cells with 100 nM β-Estradiol (E2) in medium supplemented with 10 ng/mL each of IL-7, IL-3 (Peprotech) and human colony-stimulating factor 1 (hCSF-1, kind gift of E. Richard Stanley). For reprogramming hCD4^+^ cells were plated at 500 cells/cm^2^ in gelatinised plates (12 wells) on irradiated MEF feeders in RPMI medium and pre-treated for 18 hr with E2 to induce C/EBPα. After E2 washout the cultures were switched to serum-free N2B27 medium supplemented with 10 ng/ml IL-4, IL-7 and IL-15 (Peprotech) at 2 ng/ml and treated with 2 μg/ml of doxycycline to activate OSKM. From day two onwards the N2B27medium was supplemented with 20% KSR (Life Technologies), 3 µM CHIR99021 and 1 µM PD0325901 (2i medium). A step-by-step protocol describing the reprogramming procedure can be found at Nature Protocol Exchange (<https://www.nature.com/protocolexchange/protocols/4567>).

Myc expression by flow cytometry {#s4-3}
--------------------------------

CD19 positive B cells were washed and fixed in Fix and Perm fixative (Life Technologies) for 15 min, then washed and permeabilised in Fix and Perm saponin-based permeabilisation buffer for 15 min. After permeabilisation, cells were incubated in 1x PBS/10% normal goat serum/0.3M glycine to block non-specific protein-protein interactions followed by Myc antibody at 1/76 dilution for 30 min at room temperature. The secondary antibody used was Goat Anti-Rabbit IgG H and L (Alexa Fluor 647) (Life technologies) at 1/2000 dilution for 30 min. A rabbit IgG was used as the isotype control. Cells were analysed on a BD LSRII flow cytometer. The gating strategy is described in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}.

Cell cycle analysis by EdU incorporation {#s4-4}
----------------------------------------

For cell cycle analyses cells were treated for 2 hr with EdU (Life Technologies). EdU staining was performed using the Click-IT EdU Cytometry assay kit (Life Technologies) at room temperature following the manufacturer's instructions. Briefly, cells were washed in PBS and fixed in Click-iT fixative for 15 min. After washing they were permeabilised in 1 × Click iT saponin-based permeabilisation buffer for 15 min. The EdU reaction cocktail (PBS, CuSO~4~, Alexa Fluor 488 azide and buffer additive as per manufacturer's protocol) was added to the cells for 30 min and then washed in 1% BSA/PBS. After staining, cells were analysed on a BD LSRII flow cytometer. The gating strategy is described in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}.

FACS analyses of transdifferentiation {#s4-5}
-------------------------------------

B cell to macrophage transdifferentiation was monitored by flow cytometry using antibodies against Mac-1 (clone 44, BD Pharmingen) and CD19 (1D3, BD Pharmingen) labelled with APC and PeCy-7, respectively. After staining, cells were analysed on a BD LSRII flow cytometer. The gating strategy is described in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}.

RNA extraction {#s4-6}
--------------

To remove the feeders, cells were trypsinised and pre-plated for 30 min before RNA isolation with the miRNeasy mini kit (Qiagen). RNA was eluted from the columns using RNase-free water and quantified by Nanodrop. cDNA was produced with the High Capacity RNA-to-cDNA kit (Applied Biosystems). qRT-PCR analyses qRT-PCR reactions were set up in triplicate with the SYBR Green QPCR Master Mix (Applied Biosystems). Reactions were run on an AB7900HT PCR machine with 40 cycles of 30 s at 95°C, 30 s at 60°C and 30 s at 72°C.

Viral vector and infection {#s4-7}
--------------------------

Production of the C/EBPαER-hCD4 retroviral vector and B cell infection were performed as before ([@bib22]; [@bib21]).

Alkaline Phosphatase (AP) staining {#s4-8}
----------------------------------

AP staining was performed using the Alkaline Phosphatase Staining Kit (STEMGENT) following the manufacturer's instructions.

Library preparation and sequencing {#s4-9}
----------------------------------

Single-cell libraries from polyA-tailed RNA were constructed applying massively parallel single-cell RNA sequencing (MARS-Seq; [@bib36]) as described in [@bib27]. Single cells were FACS isolated into 384-well plates with lysis buffer and reverse-transcription primers containing the single-cell barcodes and unique molecular identifiers (UMIs). Each library consisted of two 192 single-cell pools per time point (pool a and pool b). Multiplexed pools were sequenced in an Illumina HiSeq 2500 system. Primary data analysis was carried out with the standard Illumina pipeline following the manufacturer\'s protocol.

Data pre-processing {#s4-10}
-------------------

Quality check of sequenced reads was performed with the FastQC quality control tool ([@bib3]). Samples that reached the quality standards were then processed to deconvolute the reads to cell level by de-multiplexing according to the pool and the cell barcodes, wherein the first read contains the transcript sequence and the second read the cell barcode and the UMI.

Samples were mapped and gene expression was quantified with default parameters using the RNA pipeline of the GEMTools 1.7.0 suite ([@bib46]) on the mouse genome assembly GRCm38 ([@bib18]) and Gencode annotations M8 ([@bib47]). We took advantage of the UMI information to correct for amplification biases during the library preparation, collapsing read counts for reads mapping on a gene with the same UMI and considering unambiguously mapped reads only.

Data analysis {#s4-11}
-------------

Cells with a library size \<1800 were excluded from further analysis. Genes detected in less than 50 cells or less than 15 cells per group were also excluded from further analysis, resulting in expression data for 17183 genes in 3152 cells. Size factor normalisation was applied by dividing the expression of each gene in each cell by the total number of detected mRNA molecules and multiplying by the median number of molecules across cells. An inverse hyperbolic sine transformation (log (x + sqrt(x^2^+1)), where x is the mRNA count) was then applied and the data were subsequently centred.

Dimensionality reduction, batch correction and gene expression reconstruction {#s4-12}
-----------------------------------------------------------------------------

We performed principal component analysis (PCA) by computing partial singular value decomposition (SVD) on the data matrix extracting the first 100 largest singular values and corresponding vectors using the method implemented in R in the 'irlba' package ([@bib6]). Examining singular vectors highlights the presence of batch effects between the two pools at each time point starting from component 3 ([Figure 1---figure supplement 1c](#fig1s1){ref-type="fig"}). We therefore applied a batch correction method based on finding mutual nearest neighbours between batches ([@bib31]). We used the R implementation (function 'mnn' in the 'scran' package) with k = 15 nearest neighbours, and computing the nearest neighbours on the first 2 PCA dimensions which only capture biological variation. This method corrects batch effects shared across all samples. However, partial SVD on batch corrected data shows that among the first 35 components that retain signals ([Figure 1---figure supplement 1d](#fig1s1){ref-type="fig"}) batch effects between the two pools are still present [Figure 1---figure supplement 1e](#fig1s1){ref-type="fig"}). We therefore applied independent component analysis (ICA) to decompose expression into 35 mutually independent components and estimate the relative mixing matrix that, when multiplied by the independent components, results in the observed data ([Figure 1---figure supplement 2d](#fig1s2){ref-type="fig"}). ICA separates well sample-specific batch effects from biological signal ([Figure 1---figure supplement 1f](#fig1s1){ref-type="fig"}). We filtered out components when the interquartile ranges of the distributions of component scores of the two pools do not overlap at any time point (components 3, 9, 13, 15, 16, 17, 19, 20, 21, 24, 26, 27,32, 35). A component correlated with cell position in the plate (Component 33, [Figure 1---figure supplement 1g](#fig1s1){ref-type="fig"}) was also filtered out. We then reconstructed gene expression by multiplying filtered gene loadings ([Supplementary file 1](#supp1){ref-type="supplementary-material"}) by the filtered samples scores ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) including only the selected 20 components (see [Figure 1---figure supplement 2e](#fig1s2){ref-type="fig"} for a schematic description). The resulting gene expression matrix was then normalised using quantile normalisation.

Computation of similarity index of our single cell RNA-seq data with reference cell types {#s4-13}
-----------------------------------------------------------------------------------------

We compared our data to a comprehensive atlas of murine cell types from [@bib35] that consists of uniformly re-analysed bulk and single cell RNA-seq data from 113 publications including 921 biological samples consisting of 272 distinct cell types.

We calculated a similarity score for each single cell transcriptome to each atlas cell type transcriptome as follows: we first calculated the genome wide correlation between each single cell and all cell types from the atlas. The correlation coefficient was then transformed using Fisher's z transformation: 1/2 \*ln((1 + r)/(1 r)). The vector of z-transformed correlations for each single cell was then scaled across reference cell types. In the same manner, we also compared our starting population single cell data to reference bulk expression data from different stages of B cell development from [@bib34] and from the immunological genome project ([@bib49]). Myc component increases in expression with time during reprogramming. This may fully account for the prediction of the extent of reprogramming in each cell. We therefore regress out Myc component before the computation of similarity score to derive a corrected similarity index. This was done by reconstructing both the atlas and single cell expression without the Myc component. This shows that Myc component is still well correlated with progression towards pluripotency at least at D4 ([Figure 2---figure supplement 3a](#fig2s3){ref-type="fig"}). This holds true when both Myc and cell cycle components are regressed out ([Figure 2---figure supplement 3b](#fig2s3){ref-type="fig"}).

Characterisation of the components: Gene set enrichment analysis {#s4-14}
----------------------------------------------------------------

We clustered genes according to the loadings on the components from ICA, assigning each gene to the component with highest or lowest loading. Each component therefore defines one cluster of negatively correlated genes and one of positively correlated genes. We then calculated the enrichment of each cluster for Gene Ontology categories ([@bib5]), restricting the analysis to categories including more than 10 and less than 200 genes, and hallmark signatures from the Molecular Signature database ([@bib44]). The hallmark gene set collection consists of 50 refined gene sets derived from over 6700 gene sets of the Molecular Signature Database, which are obtained from a variety of experimental approaches including gene expression profiling and binding location experiments ([@bib43]). Refinement was obtained by a combination of automated approaches and expert curation, aimed at reducing redundancy among gene sets and expression variation within gene sets ([@bib44]).

We tested significance of gene set enrichment its significance using Fisher's test. P-values were corrected for multiple testing using Benjamini-Hochberg method ([@bib7]).

Characterisation of the components: comparison to the mouse cell atlas {#s4-15}
----------------------------------------------------------------------

We compared our data to a comprehensive atlas of murine cell types ([@bib35]). We applied ICA to decompose expression of the atlas of cell types into 120 mutually independent components, and we correlated these to the components extracted from our single cell data ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}), to determine cell type specificity of single cell components. To this end, we correlate gene loadings of single cell components with the gene loadings of atlas components. We then defined the cell type specificity of a single cell component as follows: we associate single cell components and atlas components based on the highest absolute value of Pearson's correlation between the gene loadings of the single cell components and of the atlas components ([Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"}). For example, the single cell component one gene loadings best correlates with atlas component 12 gene loadings (positive correlation). We next characterise cell type specificity of each atlas component based on the dynamics of the single cell components scores (the single cells' projection onto the components) and on atlas cell type scores (projection of atlas cell type on the atlas component). For example, single cell component one negatively correlates with genes that monotonically increase during transdifferentiation. The correspondent atlas component 12 is characterised by highly negative scores of macrophage and dendritic cells. We therefore define component 12 of the atlas, and by extension also the single cell component 1, as 'a macrophage' component.

Diffusion map and diffusion pseudotime {#s4-16}
--------------------------------------

To visualise data in low dimensional space we used diffusion maps. Diffusion maps are a method for non-linear dimension reduction that learn the non-linear data manifold by computing the transition probability of each data point to its neighbours (diffusion distances). We used the R implementation by [@bib30] available in library 'dpt' version 0.6.0. The transition matrix is calculated by using ´Transitions´ function on the selected ICA components using a sigma = 0.12 for the Gaussian kernel. We also calculated diffusion pseudotime using the function 'dpt' in the same library.

t-SNE {#s4-17}
-----

We used the R implementation of t-SNE (Rtsne library). We input the 20 selected components from ICA for the starting pre-B cell population and we choose a perplexity of 30.

Differential expression analysis, clustering and heatmaps {#s4-18}
---------------------------------------------------------

We performed differential expression analysis on the reconstructed expression using 'limma' package in R, we selected genes differentially expressed at false discovery rate of 5% and with at least 1.3 fold change between adjacent time points during transdifferentiation or reprogramming. We cluster these sets of genes using hierarchical clustering with complete linkage (function hclust in R library 'fastcluster', method='complete'). Clusters are displayed the with heatmaps (function 'heatplot' in 'made4' library). We performed gene set enrichment analyses on these sets of genes and clusters using Fisher's test as explained above.

Correlation between reprogramming efficiency and myc activity {#s4-19}
-------------------------------------------------------------

Reprogramming efficiency data for different hematopoietic cell types as well as from mouse tail fibroblasts are from [@bib24]; neural stem cells, pancreatic beta cells, keratinocytes and MEFs are from [@bib39], [@bib55], [@bib1], and [@bib56], respectively. Cell reprogramming efficiencies were matched to the expression values of their Myc component, obtained from the mouse cell atlas ([@bib35]) as described above ([Figure 1---figure supplement 2a,c](#fig1s2){ref-type="fig"}). When more than one cell type from the atlas corresponded to a single cell category used for reprogramming, their Myc component values were averaged ([Supplementary file 5](#supp5){ref-type="supplementary-material"}). Myc expression in the hematopoietic lineage is the mean level across single cells of each cell type from [@bib36].

Data availability {#s4-20}
-----------------

Single cell gene expression data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO) under accession number GSE112004.
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###### Gene cluster membership and gene loadings on each independent component for each detected gene.

The sign of cluster membership is positive if the gene has the highest absolute loading on the positive side of the component and negative if the highest absolute loading is on the negative side of the component.
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###### Total mRNA count, number of detected genes, and projection onto each independent component, for each single cell.
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###### Fisher's test based gene set enrichment analysis on Gene Ontology categories (biological process) for each gene cluster derived from ICA.

Includes odds ratios, p-values and FDR, number of genes associated with each category, number and names of genes included both in the cluster and in the category.
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###### Fisher's test based gene set enrichment analysis on hallmark genesets for each gene cluster derived from ICA.

It includes odds ratio, p-value and FDR, number of genes included in each category, number and names of genes included both in the cluster and in the category.

10.7554/eLife.41627.019

###### Reprogramming efficiencies for different cell types and expression of Myc from [@bib36] and Myc component from the mouse cell type atlas.

10.7554/eLife.41627.020

###### Fisher's test based gene set enrichment analysis on both GO and hallmark gene sets for genes differentially expressed with a fold change of at least 1.3 between adjacent time points during reprogramming and transdifferentiation.

Includes odds ratio, p-value and FDR, number of genes included in each category, number and names of genes both included both in the cluster and in the category.
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###### Fisher's test based gene set enrichment analysis on both GO and hallmark gene sets for genes in the clusters shown in the heatmaps of supplementary Figure 3j-l.
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Data availability {#s7}
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Single cell gene expression data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO) under accession number GSE112004

The following dataset was generated:

HeynHRodríguez-EstebanG2018Single cell expression analysis uncouples transdifferentiation and reprogrammingNCBI Gene Expression OmnibusGSE112004

The following previously published datasets were used:

HoffmannRSeidlTNeebMRolinkAMelchersFRolinkT2002Murine bone marrow B cell precursorsNCBI Gene Expression OmnibusGSE13

TheImmunological Genome Project Consortium2009Immunological Genome Project data Phase 1NCBI Gene Expression OmnibusGSE15907
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Single cell expression analysis uncouples transdifferentiation and reprogramming\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Chris P Ponting as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Michel Nussenzweig as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Francesconi et al. have undertaken a time series experiment to compare pre-B cell transdifferentiation into macrophages, with reprogramming into iPSCs. Using single cell RNA sequencing they identify the sequential loss of B cell specific factors and the engagement of myeloid gene expression patterns during transdifferentiation. Concordantly they show that reprogramming leads to a loss of B cell identity and a gain of ESC-like transcriptional state 8 days after reprogramming. Further, they correlate these changes with a number of different factors and ultimately show that expression of Myc, and its downstream target genes, in the starting population are predictive of transdifferentiation and reprogramming efficiency. This difference is predicted by Myc expression but Myc was not demonstrated unequivocally to be causal. This model is consistent with functional experiments, which reveal that the initial starting population was heterogeneous, and consisted of 2 distinct B cell developmental stages, each with reciprocal efficiencies for transdifferentiation and reprogramming.

Essential revisions:

1\) Some decisions made in how the single cell data are processed to be poorly motivated and somewhat arbitrary. Additionally, it is not clear how the approach and experimental design taken by the authors address their specific problem, and why a simpler approach could not be taken. In particular, and rather surprisingly, the authors do not check for heterogeneity in the starting population, for instance, is there any indication of structure in the pre-stimulated cells? This could be interrogated very simplistically, particularly as the authors make pains to point out bi- and tri-modality in hard to read violin plots for latter stages post-stimulation. Subsection "Large and small pre-B cells differ reciprocally in their propensity to transdifferentiate or reprogram", last paragraph, could the small and large pre-B cells be in fundamentally different states?

In the Discussion it is said that \"a cell\'s propensity for transdifferentiation or reprogramming can be disassociated, indicating that these two types of plasticity are fundamentally different\". This is overstating the evidence because this statement discusses \"a cell\" whereas the propensity differences are evident for two different cell types (albeit one differentiation step apart). The authors appear not to show, using highly purified populations of these 2 cell types, that \"these two types of plasticity are fundamentally different.\"

OSKM includes MYC. Why does input MYC matter? Is it merely a marker for the two different cell types that differ in some other way? This needs to be clarified.

The conclusion that MYC level inhibits lineage conversion is based on a single model, which only uses one transcription factor. A general statement should not be made based only on a single model.

Analysis of open chromatin across the time points could be helpful. Does CEBPa open new chromatin or only bind to existing open chromatin sites?

2\) The reviewers agree that it is plausible that MYC expression level affects reprogramming. The evidence for this is, however, correlative: the mechanism by which MYC elicits its effects is not determined. To be definitive, the authors could demonstrate that low levels of endogenous Myc (via CRISPRi and/or knockdown) are associated with inefficient reprogramming in one (or preferably more) cell types. It may also be true that cycling cells are easier to reprogram. This may not represent a novel discovery (Tsubouchi et al., Cell 2013). Proliferating cells dilute out existing proteins when transcription rates drop, this may be needed for loss of the starting fate. More generally, at several points the authors state that \"X predicts Y\". It would be more accurate to state that \"X is correlated with Y\" since prediction implies a causality that is not proved.

3\) The Results section is hard-going at times, particularly when the reader is expected to rederive the conclusions of the text simultaneously using many different figures and panels. Examples are:a) \"We found that a signature enriched in Myc target genes (component 5, Figure 1---figure supplement 2, Supplementary file 4) best predicts speed of cell conversion and negatively correlates with the progression of cells at intermediate time points of transdifferentiation (Figure 2B, Figure 2---figure supplement 1).\" Here, the reader is requested to compare 3 figures (and 1 table) whilst figuring out what is meant by \"speed of cell conversion\". We request that you take your time to explain these observations so that the reader better appreciates this important sentence. re: Figure 2D. \"low expression of Myc targets is more strongly associated with a rapid gain of the macrophage state than with a rapid loss of the B cell state\". Again there is a need to lead the reader through this plot.

4\) The authors will need to introduce the experimental system in more detail, in particular the dox-inducible cassette encoding the 4 Yanamaka factors. Additionally, they should provide some justification for the different time points and resolution between the transdifferentiation and reprogramming experiments.

5\) When describing the results of the single cell experiments, there needs to be more specific examples of genes and their relevance. Simply describing a \'B cell program\' is uninformative. To that end, the presentation of the top 50% of expressed cells feels a little like cherry picking; the authors should present the distribution of expression for all cells, not just the top 50%.

6\) Related to the above, the last paragraph of the subsection "Single cell analysis of highly efficient transdifferentiation and reprogramming from the same cell population", should be split into 2 separate sections, and expanded to include more details as above.

7\) The subsection "Rapid transdifferentiation into macrophages is associated with low expression of Myc targets" could potentially be explained by differences in resolution of the time series experiments. The authors need to demonstrate quantitatively that there are differences in the rates of transdifferentiation versus reprogramming, and what are the potential explanations. This is not aided by the difficulty in reading many of the plots, i.e. violin plots, then stating something is evident when it has not been demonstrated. The presentation of these data needs to be clearer. It is better to provide several clear examples that illustrate the authors\' point, than to try to squeeze too many plots into a single figure panel.

8\) Subsection "The rapid transdifferentiation of cells with low Myc activity is more direct" -- it is not clear that higher Myc target expression is associated with a more persistent induction of a GMP-like state, as there is no indication of a relative time difference between Myc-high and Myc-low cells.

9\) Unsurprisingly the monocyte and macrophage components are highly correlated -- given this Figure 2F is arguably redundant.

10\) Subsection "Efficient reprogramming is associated with high expression of Myc targets" -- please confirm that the ICM component is not driven by Myc target genes; include a reference to Figure 2---figure supplement 3 for this.

11\) Would any population of cycling unsynchronized cells also show considerable variation in Myc target gene expression? A proper comparison to control populations that are synchronized or unsynchronized, e.g. ESCs, would give some indication of where these pre-B cells sit in this respect.

12\) Subsection "Variation in Myc activity reflects pre-existing variation in the starting cell population", last sentence. This statement is too strong. Specifically, at no point have the authors presented evidence about speeds or rates of transdifferentiation and/or reprogramming.

13\) Figure 3D -- can you justify the thresholds used for the FSC and SSC? In particular, in later figure panels it seems like there is a strong overlap between the \"large\" cells and \"small\" cells.

14\) a) From a more technical perspective, what is the motivation of using an inverse hyperbolic sine transformation, when a scaling factor would achieve the same result? If it does not, then demonstrate why.

b\) Additionally, correction with MNN removes batch effects that are orthogonal to the biological signal. Using only first 2 PCs will likely miss genuine MNNs, and thus will not appropriately correct batch effects embedded in deeper reduced dimensions.

c\) Subsection "Computation of similarity index of our single cell RNA-seq data with reference cell types". Was this regressed out of the similarity index, or were the Myc target genes just removed before re-computing the scores? This needs clarification. More generally, a gene is expressed, not a signature, i.e. talking about the expression of a Myc signature/component does not make biological sense -- it is an artificial construction. Say score, or loading, instead of expression.

d\) Subsection "Characterization of the components: comparison to the mouse cell atlas" -- what correlation coefficient was used here? Pearson\'s, Spearman\'s, Kendall\'s, etc.?

e\) Subsection "Diffusion map and diffusion pseudotime" -- why use a sigma of 0.12, this seems very specific?

f\) Subsection "Differential expression analysis, clustering and heatmaps" -- when describing a differential expression analysis it is standard practise to indicate the false discovery rate. Also, why use a fold change of 1.3? Again, this is a strangely arbitrary value that needs some justification.

15\) Other issues:

a\) Figure 1---figure supplement 3 caption is not complete -- sub panel indicators are missing.

b\) Abstract. Make it clearer that the two cell types are categorically different (\"only a single differentiation step apart\", Discussion, also shown in Figure 4).

c\) Figure 1I. Clarify why the 6h data were not included.

d\) Figure 1---figure supplement 2A. Justify the selections of components and cell types. Explain \"Scheme of ICA decomposition the\"

e\) Figure 1---figure supplement 4 (subsection "Rapid transdifferentiation into macrophages is associated with low expression of Myc targets") \"This is also evident from the bi- or trimodal distribution of key marker genes at intermediate time-points of reprogramming and transdifferentiation\". The bi/trimodality is not immediately evident from these violin plots so I suggest that you show the raw data for an exemplar marker gene and cell type (e.g. Nanog). In the text this is described as \"asynchronous behaviour\" yet formally this is an interpretation and at this stage in the manuscript no data supporting this has been provided.

f\) Figure 2B. Explain that the start/end point data are not shown, and say why in the legend.

g\) Explain at greater length the \"time window of highest responsiveness\".

h\) Introduction, \"homogeneous\".

i\) Subsection "Efficient reprogramming is associated with high expression of Myc targets", change \"can\" to \"could\".

j\) Explain (re: 0.01% to 25%) that the conversion processes remain unclear.

10.7554/eLife.41627.031

Author response

> Essential revisions:
>
> 1\) Some decisions made in how the single cell data are processed to be poorly motivated and somewhat arbitrary. Additionally, it is not clear how the approach and experimental design taken by the authors address their specific problem, and why a simpler approach could not be taken.

In the revised manuscript we have both better explained the motivations behind the data processing and, as detailed in the responses to individual queries below, we have also included analyses to show that alternative processing of the data give rise to the same conclusions.

The experimental design is also better introduced in the Introduction. The aim was to address how heterogeneous these 'efficient' transdifferentiation and reprogramming systems really are. Single cell RNA sequencing is the obvious unbiased approach to address this question.

> In particular, and rather surprisingly, the authors do not check for heterogeneity in the starting population, for instance, is there any indication of structure in the pre-stimulated cells? This could be interrogated very simplistically, particularly as the authors make pains to point out bi- and tri-modality in hard to read violin plots for latter stages post-stimulation.

When we initiated our experiments, we had no indication that the isolated pre-B cells are heterogeneous. Rather, this was a bold prediction that we made based on computational analyses of the single cell RNA-seq time series. We could clearly see that there was heterogeneity in the trans-differentiating and reprogramming cells. A major part of this heterogeneity related to expression of Myc target genes and this also related to variation in the total RNA content of each single cell. This could either have been heterogeneity induced by the TF pulse or heterogeneity that pre-existed in the starting cell population such that cells responded differently to the pulse. We tested this hypothesis and found that indeed the starting cell population consists of two discrete populations of cells with different sizes and cell cycle states. We show that these two populations differ substantially and reciprocally in their efficiency of trans-differentiation and reprogramming. In short, we think this study represents a great example of how unbiased single cell expression profiling can lead to completely unexpected (to us) and fundamental insights into a system that we have been studying for a very long time.

We have now included a two-dimensional t-SNE plot (Figure 3---figure supplement 1A) to show that the structure in the starting pre-B cell population largely overlaps with variation in the Myc component.

> Subsection "Large and small pre-B cells differ reciprocally in their propensity to transdifferentiate or reprogram", last paragraph, could the small and large pre-B cells be in fundamentally different states?

Small and large pre-BII cells indeed represent different cell states: large pre-BII cells have higher Myc expression and activity and are proliferating. In contrast, small pre-BII cells are Myc low and quiescent. This is shown in Figure 3A-E, Figure 3---figure supplement 1A-D, and described in the Results section.

> In the Discussion it is said that \"a cell\'s propensity for transdifferentiation or reprogramming can be disassociated, indicating that these two types of plasticity are fundamentally different\". This is overstating the evidence because this statement discusses \"a cell\" whereas the propensity differences are evident for two different cell types (albeit one differentiation step apart). The authors appear not to show, using highly purified populations of these 2 cell types, that \"these two types of plasticity are fundamentally different.\"

We show that purified small pre-BII cells trans-differentiate faster to become macrophages (Figure 3F, G) and are almost refractory to reprogramming into induced pluripotent stem cells. In contrast, large pre-BII cells (Figure 3H, I) trans-differentiate more slowly (and via a different path) but reprogram very efficiently. It is the comparison between these two very related cell types that we are making. Naively one might think that a more 'plastic' cell would respond more efficiently to both transitions. In contrast, what we see is that the cell type that reprograms better trans-differentiates worse and vice versa. We have tried to explain this better in the revised manuscript and have removed the term 'fundamentally'.

> OSKM includes MYC. Why does input MYC matter? Is it merely a marker for the two different cell types that differ in some other way? This needs to be clarified.

At the moment we cannot distinguish whether Myc activity is a marker that predicts the ability to reprogram from whether Myc is causally important in driving these differences between cell types. However, the fact that Myc levels predict the ability to reprogram across many different cell types (Figures 3J and K) and the known role of Myc in reprogramming make it a parsimonious explanation that Myc activity is causal. Based on the literature the effect of Myc expression in the starting cells could be mediated by at least three different scenarios as we now discuss in more detail:

"The Myc effect could be mediated by either one of different activities reported for the factor, or a combination of them. These include its ability to induce cell proliferation (Dang, 2012), its association with global chromatin changes (Knoepfler et al., 2006; Kieffer-Kwon et al., 2017), its capacity to transcriptionally amplify a large number of genes, including those essential for proliferation (Lin et al., 2012) and its induction of metabolic changes (Dang, 2012)."

> The conclusion that MYC level inhibits lineage conversion is based on a single model, which only uses one transcription factor. A general statement should not be made based only on a single model.

We agree and have modified the text appropriately (subsection "Variation in Myc activity reflects pre-existing variation in the starting cell population", first paragraph). Myc levels predict reprogramming efficiency across a very wide range of cell types. However, we have only shown that Myc levels inhibit the ability to trans-differentiate for a single cell fate change.

> Analysis of open chromatin across the time points could be helpful. Does CEBPa open new chromatin or only bind to existing open chromatin sites?

As we have described earlier^6,7^, C/EBPa can bind not only to sites primed by other transcription factors, but also to closed chromatin, acting as a pioneer factor. For example, during iPS reprogramming C/EBPa primes pluripotency-associated enhancer regions for subsequent binding of the transcription factor Klf4^7^. Recent work by the Taipale lab has extended these observations^8^. This is now mentioned in the text (subsection "Large and small pre-B cells differ reciprocally in their propensity to transdifferentiate or reprogramrespective transdifferentiation and reprogramming propensities", second paragraph).

> 2\) The reviewers agree that it is plausible that MYC expression level affects reprogramming. The evidence for this is, however, correlative: the mechanism by which MYC elicits its effects is not determined. To be definitive, the authors could demonstrate that low levels of endogenous Myc (via CRISPRi and/or knockdown) are associated with inefficient reprogramming in one (or preferably more) cell types.

While our manuscript was under review it has been reported that the knock-out of Myc in fibroblasts prior to OSKM overexpression significantly reduces iPSC reprogramming efficiency^1^, corroborating our findings. This paper is now cited in the text.

> It may also be true that cycling cells are easier to reprogram. This may not represent a novel discovery (Tsubouchi et al., Cell 2013). Proliferating cells dilute out existing proteins when transcription rates drop, this may be needed for loss of the starting fate. More generally, at several points the authors state that \"X predicts Y\". It would be more accurate to state that \"X is correlated with Y\" since prediction implies a causality that is not proved.

This is an interesting suggestion but our data do not support the dilution model because the Myc component correlates more strongly with the gain of the macrophage or pluripotency program than the loss of B cell program (Figure 2D and J).

We have now toned down our wording and state that Myc correlates with, rather than predicts susceptibility to reprogramming into pluripotent cells.

> 3\) The Results section is hard-going at times, particularly when the reader is expected to rederive the conclusions of the text simultaneously using many different figures and panels. Examples are:a) \"We found that a signature enriched in Myc target genes (component 5, Figure 1---figure supplement 2, Supplementary file 4) best predicts speed of cell conversion and negatively correlates with the progression of cells at intermediate time points of transdifferentiation (Figure 2B, Figure 2---figure supplement 1).\" Here, the reader is requested to compare 3 figures (and 1 table) whilst figuring out what is meant by \"speed of cell conversion\". We request that you take your time to explain these observations so that the reader better appreciates this important sentence. re: Figure 2D. \"low expression of Myc targets is more strongly associated with a rapid gain of the macrophage state than with a rapid loss of the B cell state\". Again there is a need to lead the reader through this plot.

We have now extensively rewritten the Results section to make it easier to read.

> 4\) The authors will need to introduce the experimental system in more detail, in particular the dox-inducible cassette encoding the 4 Yanamaka factors. Additionally, they should provide some justification for the different time points and resolution between the transdifferentiation and reprogramming experiments.

We have now added a description of the experimental model used in the manuscript (see Introduction).

The time points chosen for the induced cell reprogramming correspond to those used in earlier publications^7,9,10^. Those for transdifferentiation are essentially as described earlier^11-13^, except that we added the 18hrs time point to permit a comparison with the reprogramming protocol. Thus, the time-points described in Figure 1A permit a direct comparison with the studies on bulk populations performed earlier. This has now been explained in the subsection "Single cell analysis of highly efficient transdifferentiation and reprogramming from the same cell population".

> 5\) When describing the results of the single cell experiments, there needs to be more specific examples of genes and their relevance. Simply describing a \'B cell program\' is uninformative. To that end, the presentation of the top 50% of expressed cells feels a little like cherry picking; the authors should present the distribution of expression for all cells, not just the top 50%.

We have now explained the functions of some of the B cell and myeloid genes shown as examples in Figure 1 and Figure 1---figure supplement 3C (see subsection "C/EBPa expression silences the B cell program and induces a progenitor state followed by a monocyte/macrophage program").

Moreover, we have shown the distribution across all cells for all the genes in the different programs regulated during reprogramming and transdifferentiation in the heatmaps in Figure 1---figure supplement 3J, K and L. We also performed a functional gene set analysis of each cluster highlighted in the heatmaps and presented this analysis in Supplementary file 6 and 7. These tables also presents the genes in each cluster that are also included in each gene set.

> 6\) Related to the above, the last paragraph of the subsection "Single cell analysis of highly efficient transdifferentiation and reprogramming from the same cell population", should be split into 2 separate sections, and expanded to include more details as above.

We have now introduced a new subheading entitled:

"Cell conversion trajectories suggest deterministic nature of transcription factor induced transdifferentiation and reprogramming".

We have now stated: "Our findings therefore support the notion that both transcription factor-induced transdifferentiation and reprogramming represent deterministic processes".

We have now introduced a new subheading entitled:

"C/EBPa expression silences the B cell program and induces a progenitor state followed by a monocyte/macrophage program".

We have now introduced a new subheading entitled:

"OSKM expression in C/EBPa-pulsed cells further accelerates B cell silencing and leads to the sequential upregulation of the pluripotency program".

These last two sections were also expanded to include the description of relevant genes whose expression changes plus a short conclusion.

> 7\) The subsection "Rapid transdifferentiation into macrophages is associated with low expression of Myc targets" could potentially be explained by differences in resolution of the time series experiments. The authors need to demonstrate quantitatively that there are differences in the rates of transdifferentiation versus reprogramming, and what are the potential explanations. This is not aided by the difficulty in reading many of the plots, i.e. violin plots, then stating something is evident when it has not been demonstrated. The presentation of these data needs to be clearer. It is better to provide several clear examples that illustrate the authors\' point, than to try to squeeze too many plots into a single figure panel.

The reviewer might have misunderstood that we were trying to compare the rate/speed of reprogramming and transdifferentiation. However, what we were interested in was whether there are differences in timing among single cells within each cell fate transition. Indeed, the diffusion map in Figure 1B and even more clearly, the projection of single cells onto the B cell-, monocyte- and macrophage- specific components in Figure 1H, show that cells at 42 hours after C/EBPa induction are spread into three different clusters along the transdifferentiation trajectory: some cells are similar to those at earlier time points, others are similar to later time points and some are at an intermediate stage. This variability at intermediate time points is also visible in Figure 2A which shows the similarity of single cell transcriptome to reference macrophage transcriptome, and in Figure 1---figure supplement 4 where we substituted violin plots of single markers with dot plots, as suggested. This heterogeneity indicates that cells do not undergo transdifferentiation at the same speed but rather exhibit an asynchronous behaviour. Similar observations were made for the reprogramming trajectory (subsections "Heterogeneity at intermediate time pointssuggests asynchrony in transdifferentiation timing", "Rapid transdifferentiation into macrophages is associated with low expression of Myc targets" and "Efficient reprogramming correlates with high Myc targets expression", last paragraph).

> 8\) Subsection "The rapid transdifferentiation of cells with low Myc activity is more direct" -- it is not clear that higher Myc target expression is associated with a more persistent induction of a GMP-like state, as there is no indication of a relative time difference between Myc-high and Myc-low cells.

We respectfully disagree. From Figure 2E it is evident that the high Myc cells (green/blue) resemble GMPs up to 42hrs after C/EBPa induction, whereas the low Myc cells (yellow/orange) only show some similarity to GMPs at 18hrs after induction. In the subsection "Cells with high Myc activity transdifferentiate via a pronounced GMP-like cell state", we have now reworded the text to make this clearer.

> 9\) Unsurprisingly the monocyte and macrophage components are highly correlated -- given this Figure 2F is arguably redundant.

We have now removed Figure 2F and substituted it with the former Supplementary Figure 6.

> 10\) Subsection "Efficient reprogramming is associated with high expression of Myc targets" -- please confirm that the ICM component is not driven by Myc target genes; include a reference to Figure 2---figure supplement 3 for this.

The conclusions about similarity to ICM hold even when the Myc component is regressed out of both our single cell and the cell atlas gene expression data before calculating the similarity score. This is shown in Figure 2---figure supplement 3. We have now also added the corresponding reference relevant for this figure in the second paragraph of the subsection "Efficient reprogramming correlates with high Myc targets expression".

> 11\) Would any population of cycling unsynchronized cells also show considerable variation in Myc target gene expression? A proper comparison to control populations that are synchronized or unsynchronized, e.g. ESCs, would give some indication of where these pre-B cells sit in this respect.

We don't fully understand this point. If the reviewer suspects that the Myc component simply captures variations in cell cycle in our single cell data, we can assert that although correlated, Myc activity and cell cycle are at least partially independent. Thus, our ICA analysis distinguishes Myc targets from G2/M and S phase components (see [Author response image 1](#respfig1){ref-type="fig"}). Further, applying ICA to the cell atlas, which is based on bulk data obtained from unsynchronized cells, also reveals a Myc component distinct from the cell cycle component, which here includes both G2/M and S components.

![](elife-41627-resp-fig1){#respfig1}

Moreover, the effect of Myc expression on protein synthesis and cells size has also been experimentally shown to be independent of the cell cycle at all stages of B lymphocyte development^14^. In short, the Myc and cell cycle components are separable.

> 12\) Subsection "Variation in Myc activity reflects pre-existing variation in the starting cell population", last sentence. This statement is too strong. Specifically, at no point have the authors presented evidence about speeds or rates of transdifferentiation and/or reprogramming.

We agree with the reviewer and have now changed the sentence into the following:

"Taken together, our analyses suggest a pre-existing heterogeneity in the starting cell population, corresponding to large and small pre-BII cells. Moreover, they suggest that small pre-BII cells should transdifferentiate faster but reprogram more slowly, while large pre-BII cells should transdifferentiate more slowly but reprogram faster".

> 13\) Figure 3D -- can you justify the thresholds used for the FSC and SSC? In particular, in later figure panels it seems like there is a strong overlap between the \"large\" cells and \"small\" cells.

We assume that the reviewer refers to former Supplementary Figure 9 (current Figure 3---figure supplement 1). We agree that in these experiments the distinction between large and small cells is not entirely clear. For this reason we have introduced three gates: one for small cells with low granularity, one for large, granular cells and one for intermediate sized cells serving as a 'buffer'. The results obtained for Myc expression justify this admittedly somewhat arbitrary separation.

> 14\) a) From a more technical perspective, what is the motivation of using an inverse hyperbolic sine transformation, when a scaling factor would achieve the same result? If it does not, then demonstrate why.

Inverse hyperbolic sine transformation, defined as log(x+(χ2+1)^1/2^), is a log-like transformation commonly used in RNA-seq analyses. It has the advantage over logarithmic transformation that it is defined for 0 counts. It tends to log(2x) for large x and to log(1) = 0 for small x. It is therefore equivalent to log (x +1), which is also a commonly used transformation for RNA-seq data. This transformation makes the distribution of counts closer to a normal distribution although distributions among single cells are not comparable. The scaling factor on the other hand serves the purpose of making the distribution of expression values comparable among cells despite different number of total reads. Therefore, applying a scaling factor (which we also do) and transforming the data using inverse hyperbolic sine transformation are two distinct but not mutually exclusive procedures that serve different purposes.

> b\) Additionally, correction with MNN removes batch effects that are orthogonal to the biological signal. Using only first 2 PCs will likely miss genuine MNNs, and thus will not appropriately correct batch effects embedded in deeper reduced dimensions.

Some batch effects embedded in reduced dimensions might be missed at this step but we further removed any residual batch effects by applying ICA extracting 35 components (which capture all the meaningful variance in the data) and filtering out 15 independent components showing residual batch effects, in particular time point specific batch effects which were not captured by MNN. This is explained in Materials and methods (subsection "Dimensionality reduction, batch correction and gene expression reconstruction") and illustrated in Figure 1---figure supplement 1.

Moreover, we have tried to use MNN batch correction using the first 35 PCs but after applying ICA and extracting 35 independent components we still find components capturing batch effects, including time point-specific batch effects (see for example component 9 and component 24 in [Author response image 2](#respfig2){ref-type="fig"}).

![](elife-41627-resp-fig2){#respfig2}

> c\) Subsection "Computation of similarity index of our single cell RNA-seq data with reference cell types". Was this regressed out of the similarity index, or were the Myc target genes just removed before re-computing the scores? This needs clarification.

The Myc component was regressed out of the expression data before re-computing the similarity scores. This is now explained better in the Materials and methods section and reads as follows.

"We therefore regress out the Myc component before computation of the similarity index to derive a corrected similarity index. This was done by reconstructing both the cell atlas and our single cell expression data without the Myc component".

> More generally, a gene is expressed, not a signature, i.e. talking about the expression of a Myc signature/component does not make biological sense -- it is an artificial construction. Say score, or loading, instead of expression.

We now changed this into Myc target gene expression.

> d\) Subsection "Characterization of the components: comparison to the mouse cell atlas" -- what correlation coefficient was used here? Pearson\'s, Spearman\'s, Kendall\'s, etc.?

It's a Pearson's correlation. This is now specified.

> e\) Subsection "Diffusion map and diffusion pseudotime" -- why use a sigma of 0.12, this seems very specific?

The diffusion map is just for visualization purposes. We used the 'find_sigmas' function in the R library 'destiny' to automatically select the sigma of the Gaussian kernel. This function suggested a sigma of 0.1. With this value however, the trajectories look very compressed and difficult to visualize. That is the only reason we chose a slightly larger sigma of 0.12. We have now included the sigma 0.1 and sigma 0.15 versions to show the effect of varying sigma in Figure 1---figure supplement 2F. As can be appreciated, the main message of the figure does not change if we use sigma = 0.1, 0.12 or 0.15 ([Author response image 3](#respfig3){ref-type="fig"}).

![](elife-41627-resp-fig3){#respfig3}

> f\) Subsection "Differential expression analysis, clustering and heatmaps" -- when describing a differential expression analysis it is standard practise to indicate the false discovery rate. Also, why use a fold change of 1.3? Again, this is a strangely arbitrary value that needs some justification.

All genes presented in the heatmaps are differentially expressed at 5% FDR. However, with so many cells even small changes in gene expression are significant at 5% FDR. Thus, we added an additional fold change cut off to reduce the number of genes visualized in the heatmaps. We agree this cut off is arbitrary, however it is as arbitrary as any other cut off on fold change or FDR. We based our conclusions on gene set enrichment analysis, which is robust against the inclusion or exclusion of single genes close to the threshold. Repeating the analysis with more or less stringent cut off on the fold change does not alter the conclusions on the processes that are regulated during transdifferentiation and reprogramming. For example, 126 genes are upregulated with a fold change of 1.3 between 6h and 18h after C/EBPa induction. If we further restrict the cut off to 1.4, the number of genes is reduced to 67 and if we use a cut off of 1.2 it increases to 288. However, the gene set enriched categories that are over represented among these genes are basically the same (innate immune response, cytokine production, inflammation, see attached excel table), showing that our analysis is robust even when changing thresholds.

> 15\) Other issues:
>
> a\) Figure 1---figure supplement 3 caption is not complete -- sub panel indicators are missing.

We have now corrected this.

> b\) Abstract. Make it clearer that the two cell types are categorically different (\"only a single differentiation step apart\", Discussion, also shown in Figure 4).

We have now simplified and modified the Abstract accordingly

> c\) Figure 1I. Clarify why the 6h data were not included.

We have now included this time point.

> d\) Figure 1---figure supplement 2A. Justify the selections of components and cell types. Explain \"Scheme of ICA decomposition the\"
>
> e\) Figure 1---figure supplement 4 (subsection "Rapid transdifferentiation into macrophages is associated with low expression of Myc targets")\"This is also evident from the bi- or trimodal distribution of key marker genes at intermediate time-points of reprogramming and transdifferentiation\". The bi/trimodality is not immediately evident from these violin plots so I suggest that you show the raw data for an exemplar marker gene and cell type (e.g. Nanog).

We now better explain the selection of components and cell types in the Materials and methods section. It now reads as follows:

"Characterization of the components: comparison to the mouse cell atlas. We compared our data to a comprehensive atlas of murine cell types (Hutchins et al., 2017). \[...\] We then defined the cell type specificity of a single cell component based on the cells that have the most extreme distribution in the sample scores of the atlas component(s) with the highest absolute Pearson's correlation values with the single cell component." We also now show dot plots instead of violin plots in Figure 1---figure supplement 4."

> In the text this is described as \"asynchronous behaviour\" yet formally this is an interpretation and at this stage in the manuscript no data supporting this has been provided.

We have now modified this into: "apparent asynchronous behaviour".

> f\) Figure 2B. Explain that the start/end point data are not shown, and say why in the legend.

We now included a sentence in the legend clarifying this (Figure 2B legend).

> g\) Explain at greater length the \"time window of highest responsiveness\".

We have now added a sentence to explain what is meant by this, referring to our earlier work: "Previous work testing different times of C/EBPa induction in pre-B cells before OSKM induction showed that an 18h treatment elicited a maximal enhancement of the cells' reprogramming efficiency. Longer exposures, driving the cells into a macrophage-like state, decreased the efficiency^9^, raising the possibility that an accelerated transdifferentiation of the small cells towards macrophages moves them out of the time window required for high responsiveness."

> h\) Introduction, \"homogeneous\".

Done.

> i\) Subsection "Efficient reprogramming is associated with high expression of Myc targets", change \"can\" to \"could\".

We corrected this.

> j\) Explain (re: 0.01% to 25%) that the conversion processes remain unclear.

We have now added: varies widely, ranging between 0.01% for T lymphocytes to 25% for GMPs for unclear reasons.
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